Prenatal management of congenital human cytomegalovirus infection in seropositive pregnant patients treated with azathioprine

Paolo Ivo Cavoretto, Chiara Fornara, Cristina Baldoli, Alessia Arossa, Milena Furione, Massimo Candiani, Patrizia Rovere Querini, Graziano Barera, Antonella Poloniato, Gerarda Gaeta, Arsenio Spinillo, Daniele Lilleri

Research output: Contribution to journalArticle

Abstract

The risk of HCMV transmission to the fetus in pregnant women receiving immunosuppressive agents is unknown. We describe two cases of pregnant women with evidence of pre-conception HCMV protective immunity receiving azathioprine for ulcerative colitis or systemic lupus erythematosus. Both women reactivated the HCMV and transmitted the infection to the fetuses. One newborn showed unilateral hearing deficits and brain abnormalities while the other was asymptomatic. The mother of the symptomatic newborn had low levels of total and HCMV-specific blood CD4+ T cells. Women receiving immunosuppressive agents deserve information about the risk of HCMV congenital infection and should be monitored for HCMV infection during pregnancy. Their newborns should be screened for HCMV congenital infection.

Original languageEnglish
Article number542
JournalDiagnostics
Volume10
Issue number8
DOIs
Publication statusPublished - Aug 2020

Keywords

  • Azathioprine
  • Congenital cytomegalovirus infection
  • Fetal MRI
  • Pregnancy
  • Ultrasound

ASJC Scopus subject areas

  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Prenatal management of congenital human cytomegalovirus infection in seropositive pregnant patients treated with azathioprine'. Together they form a unique fingerprint.

  • Cite this